Abstract Library

#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,

Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,

#2839 The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan

Introduction: Japanese Neuroendocrine Tumor Society (JNETS) has published the first edition of clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in 2015. Then, according to an update on the diagnosis and management of GEP-NEN in Japan. Revised clinical practice guidelines, the second edition, has just published in 2019.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ito T, Masui T, Komoto I,

Keywords: GEP-NEN, Guideline, Japan,

#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice

Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Teulé A, Alonso T, González E, De La Cruz G, Houchard A,

Keywords: NET, lanreotide, pancreas, study,

#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice

Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Metz D

Authors: Metz D, Liu E, Joish V, Huynh L, Cheng M,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin, tumor growth, progression-free survival,

#2175 A Retrospective Analysis of 344 Cases with Neuroendocrine Neoplasms

Introduction: Ki-67 is a nuclear protein that is strictly associated with cellular proliferation，acting as a cellular marker for proliferation in clinical practice to determine the degree to which the tumor cells are duplicating. Ki-67 index strongly ties to the prognosis and provides guiding significance to clinical decisions.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Liu Z, Zhao H, Wu Y, Jiang L, Shi S,

Keywords: ki-67 index, neuroendocrine neoplasm, prognosis,